Form 4 for NRIX Nurix Therapeutics, Inc.
Accepted 2022-06-01 00:00:00 ET · period of report 2022-05-31 · accession 0001209191-22-033200 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-06-01 | 2022-05-31 | NRIX | van Houte Hans | CFO | M - OptEx | $0.84 | +68.3K | 70.5K | +3,122% | +$57.4K |
| D | 2022-06-01 | 2022-05-31 | NRIX | van Houte Hans | CFO | M - OptEx | $0.00 | -68.3K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-31 | M | A | 68,333 | $0.84 | 70,522 | D | — | — | |
| 2 | Derivative | Employee Stock Option (right to buy) | 2022-05-31 | M | D | 68,333 | $0.00 | 0 | D | $0.84 · — to 2026-04-26 | 68,333 Common Stock | (F1) The option is fully vested. |